W. Michael Korn, MD

Associate Professor in Residence, Department of Medicine (Gastroenterology and Medical Oncology), UCSF

Phone: (415) 353-9888 (appts)
Box 1705, UCSF
San Francisco, CA 94143-1705

View on UCSF Profiles

Additional Websites

• Physician Referral Directory
• Lab Website

Education

Philipps University of Marburg, Germany, Continuing Education, 1981 - 1984, Medicine
Heinrich-Heine University of Düsseldorf, Germany, Approbation as Physician, 1984 - 1988, Medicine
Philipps University of Marburg, Germany, Medical Doctorate, 1993
University of Bern, Switzerland, Internship, 1997, Medicine

Professional Experience

• 1988-1992
  Physician in Training, Ev. Krankenhaus Dinslaken, Germany
• 1992-1996
  Physician in Training, West German Cancer Center, University of Essen, Medical School, Essen, Germany
• 1996
  Certified Internist, West German Cancer Center, University of Essen, Medical School, Essen, Germany
• 1996
  Interim Head, Laboratory of Tumor Cytogenetics, West German Cancer Center, University of Essen, Medical School, Essen Germany
• 1996-1997
  Postdoctoral Fellow, Laboratory Medicine (F. Waldman), UCSF Cancer Center, UCSF
• 1997
  Postdoctoral Fellow, Cancer Research Institute (F. McCormick), UCSF Cancer Center, UCSF
• 1997-1999
  Assistant Research Biochemist, Cancer Research Institute, UCSF Cancer Center, UCSF
• 1999-2004
  Assistant Adjunct Professor of Medicine, Division of Gastroenterology, UCSF
• 2004-2006
  Assistant Adjunct Professor of Medicine, UCSF
• 2006-present
  Associate Professor of Medicine in Residence, Divisions of Gastroenterology and Medical Oncology, UCSF
• 2008-2011
  Co-Director, Center of Molecular Oncology, UCSF

Honors & Awards

• 1996
  Mildred-Scheel Research Fellowship, Mildred Scheel Stiftung e.V., Germany
• 2000
  UCSF REAC Award
• 2000
  American Cancer Society Individual Research Award
• 2001, 2002
  Hellman Family Award
• 2005
  UCSF THANKS Star Award
• 2008
  Cancer League Award
• 2008
  Tip Your Heart Foundation Award
• 2009
  Helen Diller Family Quality Award

Selected Publications

1. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001.
   View on PubMed
2. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003.
   View on PubMed
3. Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 1; 9(8):830-87.
   View on PubMed
4. Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, Korn WM. ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor. Mol Cancer. 2011; 10:91.
   View on PubMed
5. Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl). 2011 Sep; 89(9):877-89.
   View on PubMed
6. Bagheri N, Shiina M, Lauffenburger DA, Korn WM. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol. 2011 Feb; 7(2):e1001085.
   View on PubMed
7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
   View on PubMed
8. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75.
   View on PubMed
9. Shiina M, Lacher MD, Christian C, Korn WM. RNA interference-mediated knockdown of p21(WAF1) enhances anti-tumor cell activity of oncolytic adenoviruses. Cancer Gene Ther. 2009 Nov; 16(11):810-9.
   View on PubMed
10. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009 Jan 15; 69(2):565-72.
    View on PubMed
11. Lu DC, Theodore P, Korn WM, Chou D. Esophageal erosion 9 years after anterior cervical plate implantation. Surg Neurol. 2008 Mar; 69(3):310-2; discussion 312-3.
    View on PubMed
12. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 2007 Feb; 14(2):139-50.
    View on PubMed
13. Korn WM, Macal M, Christian C, Lacher MD, McMillan A, Rauen KA, Warren RS, Ferrell L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 2006 Aug; 13(8):792-7.
    View on PubMed
14. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain A, Akhurst RJ, Korn WM. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 2006 Feb 1; 66(3):1648-57.
    View on PubMed
15. Korn WM. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):405-16.
    View on PubMed
16. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003 May 1; 63(9):2088-95.
    View on PubMed
17. Anders M, Hansen R, Ding RX, Rauen KA, Bissell MJ, Korn WM. Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1943-8.
    View on PubMed
18. Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002 Jan 7; 86(1):5-11.
    View on PubMed
19. Korn WM. Moving toward an understanding of the metastatic process in hepatocellular carcinoma. World J Gastroenterol. 2001 Dec; 7(6):777-8.
    View on PubMed
20. Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med. 2000 Oct; 6(10):1128-33.
    View on PubMed

View on UCSF Profiles